[go: up one dir, main page]

WO2001068700A3 - Regulation of human substance p-like g protein-coupled receptor - Google Patents

Regulation of human substance p-like g protein-coupled receptor Download PDF

Info

Publication number
WO2001068700A3
WO2001068700A3 PCT/EP2001/002861 EP0102861W WO0168700A3 WO 2001068700 A3 WO2001068700 A3 WO 2001068700A3 EP 0102861 W EP0102861 W EP 0102861W WO 0168700 A3 WO0168700 A3 WO 0168700A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
diseases
disease
protein
reagents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2001/002861
Other languages
French (fr)
Other versions
WO2001068700A2 (en
Inventor
Shyam Ramakrishnan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Priority to EP01915335A priority Critical patent/EP1294758A2/en
Priority to AU2001242459A priority patent/AU2001242459A1/en
Publication of WO2001068700A2 publication Critical patent/WO2001068700A2/en
Publication of WO2001068700A3 publication Critical patent/WO2001068700A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reagents which regulate human substance P G protein-coupled receptor (SP-GPCR) protein and reagents which bind to human SP-GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, urinary incontinence, inflammatory diseases (e.g., arthritis, psoriasis, asthma and inflammatory bowel disease), anxiety, depression or dysthymic disorders, cluster headache, colitis, psychosis, pain, allergies such as eczema and rhinitis, chronic obstructive airways disease, hypersensitivity disorders such as poison ivy, vasospastic diseases such as angina, migraine and Reynaud's disease, fibrosing and collagen diseases such as scleroderma and eosinophilic fascioliasis, reflex sympathetic dystrophy such as shoulder/hand syndrome, addiction disorders such as alcoholism, stress related somatic disorders, peripheral neuropathy, neuralgia, neuropathological disorders such as Alzheimer's disease, AIDS related dementia, diabetic neuropathy and multiple sclerosis, disorders related to immune enhancement or suppression such as systemic lupus erythematosus, and rheumatic diseases such as fibrositis.
PCT/EP2001/002861 2000-03-17 2001-03-14 Regulation of human substance p-like g protein-coupled receptor Ceased WO2001068700A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01915335A EP1294758A2 (en) 2000-03-17 2001-03-14 Regulation of human substance p-like g protein-coupled receptor
AU2001242459A AU2001242459A1 (en) 2000-03-17 2001-03-14 Regulation of human substance p-like g protein-coupled receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18997200P 2000-03-17 2000-03-17
US60/189,972 2000-03-17

Publications (2)

Publication Number Publication Date
WO2001068700A2 WO2001068700A2 (en) 2001-09-20
WO2001068700A3 true WO2001068700A3 (en) 2002-03-21

Family

ID=22699530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/002861 Ceased WO2001068700A2 (en) 2000-03-17 2001-03-14 Regulation of human substance p-like g protein-coupled receptor

Country Status (3)

Country Link
EP (1) EP1294758A2 (en)
AU (1) AU2001242459A1 (en)
WO (1) WO2001068700A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03003902A (en) 2000-11-03 2004-04-02 Univ California Prokineticin polypeptides, related compositions and methods.
JPWO2003027672A1 (en) * 2001-09-20 2005-01-13 山之内製薬株式会社 Novel screening method using prokineticin receptor
US20030203847A1 (en) * 2002-02-28 2003-10-30 Millennium Pharmaceuticals, Inc. Methods and compositions in treating pain and painful disorders using 9949, 14230, 760, 62553, 12216, 17719, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 16314, 1613, 1675, 9569 or 13424 molecules

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046620A1 (en) * 1997-04-17 1998-10-22 Millennium Pharmaceuticals, Inc. A novel human g-protein coupled receptor
WO2000034334A1 (en) * 1998-12-10 2000-06-15 Synaptic Pharmaceutical Corporation DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
WO2001016309A1 (en) * 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2001036471A2 (en) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998046620A1 (en) * 1997-04-17 1998-10-22 Millennium Pharmaceuticals, Inc. A novel human g-protein coupled receptor
WO2000034334A1 (en) * 1998-12-10 2000-06-15 Synaptic Pharmaceutical Corporation DNA ENCODING A MAMMALIAN RECEPTOR (fb41a) AND USES THEREOF
WO2001016309A1 (en) * 1999-08-27 2001-03-08 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
WO2001036471A2 (en) * 1999-11-17 2001-05-25 Arena Pharmaceuticals, Inc. Endogenous and non-endogenous versions of human g protein-coupled receptors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] 1 October 2000 (2000-10-01), XP002176970, retrieved from HOMO SAPIENS Database accession no. Q9NTT0 *
DATABASE WPI Section Ch Week 200123, Derwent World Patents Index; Class B04, AN 2001-226684, XP002176971 *

Also Published As

Publication number Publication date
AU2001242459A1 (en) 2001-09-24
WO2001068700A2 (en) 2001-09-20
EP1294758A2 (en) 2003-03-26

Similar Documents

Publication Publication Date Title
Gurevich et al. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors
Dekens et al. Lipocalin 2 as a link between ageing, risk factor conditions and age-related brain diseases
CN1178932C (en) Amide derivatives
CN1243724C (en) Amide Derivatives Used as Cytokine Inhibitors
Nakayama Macrophage recognition of crystals and nanoparticles
CN1146542C (en) Benzamide derivatives and their use as cytokine inhibitors
WO2007036745A3 (en) Interleukin-13 antibody composition
CN1321151A (en) Chemical compounds
WO2001068700A3 (en) Regulation of human substance p-like g protein-coupled receptor
WO2007009083A3 (en) Compounds with activity at retinoic acid receptors
WO2001087929A3 (en) Regulation of human dopamine-like g protein-coupled receptor
CN88100650A (en) Anti-inflammatory agent
WO2002062848A3 (en) Regulation of cc chemokine receptor 3 (ccr3) expression
CN1735595A (en) Substituted Alkylamidopiperidines
DE60226414D1 (en) HUMAN G-PROTEIN COUPLED RECIPE
Lieberman et al. High cholesterol at the heart of phagolysosomal damage
Więckowski et al. Serotonin 5-HT6 receptor ligands and butyrylcholinesterase inhibitors displaying antioxidant activity—design, synthesis and biological evaluation of multifunctional agents against Alzheimer’s disease
Yang et al. Multiple roles of SMC5/6 complex during plant sexual reproduction
Neuser et al. Mechanical and Microstructure Characterisation of the Hypoeutectic Cast Aluminium Alloy AlSi10Mg Manufactured by the Twin-Roll Casting Process
Nikolaienko et al. Endocytic adapter intersectin 1 interacts with cytoskeletal protein STOP: YSF. 82
Katavolos The role of Clara cells in the pathogenesis of equine recurrent airway obstruction
Weitzman Stress and alcohol
Wines et al. Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
KOTAKI et al. A tuning method for PID controller under consideration of changes in plant characteristics
Raymond et al. Production of IgGs with a human-like sialylation in CHO cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001915335

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10220289

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001915335

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001915335

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP